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Abstract 
On March 11, 2020, the World Health Organisation (WHO) observed the scale of epidemic risk and declared the state of the COVID-19 
pandemic. Most countries, including Poland, implemented national and local emergency management plans to deal with the imminent 
threat of SARS-CoV-2 infection, one of the most serious in this century, according to many experts. In the era of pandemic, during which 
an epidemiological regime and social distancing are constantly recommended, and routine medical care and planned surgical proce-
dures have been postponed or significantly reduced, patients and their physicians have to struggle on a daily basis with difficult access 
to diagnostic and therapeutic procedures. This is a great challenge for both groups. The aim of this study is to assess the current state of 
knowledge about thyreological diseases during the COVID-19 pandemic and to provide indications for the introduced therapeutic changes 
on the basis of recent scientific literature published up to December 2020 and searches of the PubMed, Google Scholar, EMBASE, and Web 
of Science databases, which searched for keywords related to SARS-CoV-2 and its influence on thyreology problems. The main focus was 
on diagnostic and therapeutic differences in the era of the COVID-19 pandemic, bearing in mind the most common endocrinopathies, i.e. 
hypothyroidism and hyperthyroidism, as well as advantages and disadvantages and possibilities of using telemedicine in the common 
practice of a specialist physician. (Endokrynol Pol 2021; 72 (2): 171–178)
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Introduction 
On March 11, 2020, the World Health Organisation 
(WHO) observed the scale of epidemic risk, which at 
that time comprised more than 118,000 cases in 114 
countries, including 4291 fatalities, and declared the 
state of the COVID-19 pandemic [1]. Severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
was first reported in Wuhan, China, which had a huge 
impact on China and the world. The disease caused by 
SARS-CoV-2 was named as coronavirus disease 2019 
(COVID-19) [2].
Most countries, including Poland, implemented na-
tional and local emergency management plans to deal 
with the imminent threat of SARS-CoV-2 infection, one 
of the most serious in this century, according to many 
experts. From March 4, 2020, when the first coronavirus 
case was registered in Poland, until mid-December this 
year, more than 1,300,000 confirmed SARS-CoV-2 infec-
tions were reported, including more than 28 thousand 
fatalities [3, 4]. In the era of the pandemic, during which 
an epidemiological regime and social distancing are 
constantly recommended, and the routine medical care 
and planned surgical procedures have been postponed 
or significantly reduced, patients and their physicians 
have to struggle on a daily basis with difficult access to 
diagnostic and therapeutic procedures. This is a great 
challenge for both groups [5, 6].
The aim of this study is to assess the current state 
of knowledge about thyreological diseases during the 
COVID-19 pandemic and to provide indications for the 
introduced therapeutic changes.
How to treat hypothyroidism effectively
Hypothyroidism is one of the most common endo-
crinopathies. All these symptoms adversely affect the 
course of infection with the SARS-CoV-2 virus. The 
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thyroid-stimulating hormone (TSH) level is the most 
sensitive test in hypothyroidism of primary origin, 
and the sensitivity of measurement is estimated to be 
above 95%, while specificity is about 90%. The TSH is 
excreted by pulsation, with low pulse amplitude and 
long T1/2. However, its daily variations are very small 
and are not significant in routine diagnostics. It is rec-
ommended that the TSH determination is carried out in 
the morning, preferably after a good night’s sleep, but 
it can be performed also during the day. It is necessary 
during fasting, because a meal inducing somatostatin 
secretion may inhibit TSH secretion in this mechanism 
[19–21]. On the other hand, the change of the TSH level 
after taking L-T4 dose (half-life = 7–8 days) occurs with 
some delay; thus, it is not important whether the TSH 
determination will be carried out after the morning 
drug administration or on a completely empty stomach 
[14, 19]. However, it is important for the determination 
of FT4, and therefore in this case it is recommended 
that the test be performed before taking the morning 
L-T4 dose. In fact, the reference values of TSH levels, 
for the whole population, range from 0.25–0.4 mIU/L 
to 4.2–4.9 mIU/L, depending on the laboratory method 
used; however, the target TSH levels should vary de-
pending on the age and clinical status of the patient, 
as shown in Table 1. Therefore, individualisation of the 
treatment target for hypothyroidism is an important 
part of the therapy in the present day. Moreover, me-
dicinal products containing L-T4 are characterised by 
a narrow therapeutic range. For this reason, in choosing 
an appropriate dose of L-T4, a personalised approach 
subclinical form represents between 3% and 15% of 
all diseases in the world, while explicit hypothyroid-
ism occurs in 0.3–0.8% of the population [7–9]. It is 
characterised by a deficiency of peripheral thyroid 
hormones: thyroxine (FT4) and triiodothyronine (FT3), 
and although it generally seems quite easy to diagnose 
and treat, it can even be fatal in severe cases if the appro-
priate therapy is not implemented. Clinical symptoms 
vary individually, depending on age, gender, or cause. 
Most adults show signs of reduced metabolism, such 
as generalised fatigue, progressive drowsiness, cold 
intolerance, weight gain, gastrointestinal disorders, as 
well as reduced tone of voice or memory and concentra-
tion disorders. Dry, peeling, thick, and cold skin, hair, 
eyebrows, and eyelashes loss, and generalised swelling 
of the eyelids, face, or whole body occur. Moreover, it 
is possible to observe bradycardia, tachyarrhythmia, or 
diastolic hypertension. All these symptoms adversely 
affect the course of infection with the SARS-CoV-2 
virus. As a result, among others, the comfort of life is 
deteriorated, occupational performance is reduced, 
and the risk of cardiovascular disease is increased. In 
the case of hypothyroidism, we also observe lipid and 
carbohydrate disorders [10-15]. The standard method 
of treatment is hormone replacement therapy with 
levothyroxine (L-T4), which is carried out chronically, 
until the end of life, in an endocrinology clinic or gen-
eral practice [4,9].
Both the American Thyroid Association (ATA) and 
European societies — the European Thyroid Associa-
tion (ETA) and the British Thyroid Association (BTA), 
state in their latest reports that so far no patients with 
hypothyroidism have been reported to be at greater 
risk of COVID-19 infection or of a more serious clinical 
course of the infection, especially if they are pharmaco-
logically balanced. They emphasise that autoimmune 
thyroid disease does not cause immunosuppression, 
including that of the p/virus [16–18]. Additionally, BTA 
states that there is also no evidence of more frequent 
infections in patients with poorly controlled thyroid 
disease. Although there are currently no clear reports 
that the SARS-CoV-2 virus can in any way affect the 
function of the thyroid gland, in patients with unbal-
anced, explicit hypothyroidism, in case they become ill, 
it can be expected that the clinical course of disease may 
be more complex, and this is due to different systemic 
relationships. Therefore, it is important that patients 
do not interrupt L-T4 substitution treatment during 
the pandemic [17, 18].
The aim of hypothyroidism treatment is to relieve 
symptoms of the disease, normalise the TSH concen-
tration, and avoid underdosing or overdosing of L-T4. 
As important as normalisation of the patient’s clinical 
status is biochemical equalisation. Determination of the 
Table 1. Target thyroid-stimulating hormone (TSH) 
concentration depending on the age and clinical status of the 
patient according to Biondi et al. [19]
Age [years]/Clinical status Serum TSH concentration [mU/L] 
Planned pregnancy Lower norm range < 1.2
Pregnancy I trimester < 2.5
Pregnancy II and III trimester < 2.5 or < 3.0
Children with congenital 
hypothyroidism
< 5.0, optimally 0.5–2.0 with FT4 
concentration in the upper normal 
range at 1 year of age
Young adults 1.0–2.5
Middle age 1.0–3.0
≤ 65 > 4.5
60–70 > 6.0
70–80 > 7.0–8.0
Central hypothyroidism FT4 in the upper half of the norm
Thyroid cancer According to the principles of thyroid cancer stratification
FT4 — free thyroxine
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to each patient should be adopted to avoid under- or 
overdosing.
For several years in the United States and in some 
European countries, and recently also in Poland, a new 
preparation containing a liquid form of LT-4 produced 
as an oral solution of L-T4 sodium in purified water and 
glycerol has been available. Many scientific papers pub-
lished so far have pointed out that the liquid L-T4 was 
more effective than the previously commonly used pill 
form of L-T4, especially in patients with absorption dis-
orders as a result of taking other drugs, diseases of the 
digestive system, or undergoing bariatric surgery. Bet-
ter pharmacokinetics of liquid L-T4 in patients without 
malabsorption syndrome have also been confirmed: pa-
tients undergoing replacement or suppressive therapy, 
who changed their tablet to liquid form in an equivalent 
dose, achieved better hormone control and required 
less frequent TSH measurements. The drug also proved 
to be effective and easy to use in patients fed through 
an enteral probe. Interestingly, liquid L-T4 seems to be 
equally effective when taken just before or during the 
first meal of the day. The analysis of usefulness of the 
drug in particular groups of patients, including new-
borns, pregnant women, and the elderly, confirmed the 
high value and safety of L-T4 liquid therapy. However, 
it should be emphasised that in the population of exam-
ined newborns, a higher incidence of TSH suppression 
was observed with an equivalent dose of liquid L-T4 
compared to tablet therapy. Therefore, special atten-
tion should be paid to this group of patients in order 
to avoid an excessive drug dose [22–30].
Also, in view of this group of patients, who, de-
spite an appropriate dose of L-T4 tablet form, did not 
achieve satisfactory effects of biochemical equalisation, 
the change to liquid form of the preparation should 
be considered. It is also important to remember that 
in spite of proper biochemical equilibrium in about 
10% of patients, unfortunately, no satisfactory clinical 
equilibrium, i.e. improvement in quality of life (QOL), 
is achieved in the subjective assessment of a patient [14, 
31]. So far, despite the fact that the brain is considered 
a target organ for thyroid hormones, it has not been 
proven that there is a reference concentration for TSH 
that would improve the patient’s mood or cognitive 
function. Samuels MH et al. have shown that despite the 
objective lack of benefit, patients who received higher 
doses of L-T4, with lower TSH values, reported an im-
provement in mental function, which is undoubtedly 
very important in the era of the COVID-19 pandemic, 
when the sanitary regime and social distancing play key 
roles in the fight against SARS-CoV-2 infections [32].
However, it should not be forgotten that prepara-
tions of dried thyroid, FT3, or complex FT4 with FT3 are 
also available on the market. Many randomised studies 
indicate that therapy with a mixture of synthetic doses 
of liothyronine (L-T3) and L-T4 in different proportions, 
although non-physiological, is safe and seems to be 
effective in controlling the symptoms of hypothyroid-
ism. Patients report faster improvement of mood as 
well as cessation of depressive disorders. In particular, 
this is observed in patients with a genetic defect in 
deiodinase activity. On the other hand, this type of 
therapy may induce side effects, such as a higher risk 
of drug overdose and the appearance of symptoms of 
hyperthyroidism, including cardiac arrhythmias and 
hypertension. In addition, it is impossible to maintain 
the most physiologically similar level of free thyroid 
hormones, thus making it difficult to individualise the 
dose for each patient, and it may also adversely affect 
the course of SARS-CoV-2 virus infection [19, 32–35].
A preparation containing FT3 alone in the form of 
synthetic L-T3 sodium is also available on the market. 
However, L-T3 has a short half-life and is rapidly ab-
sorbed, resulting in large non-physiological variations 
in its serum concentration. In addition, twice-a-day 
supply of the drug is required. Although dried thyroid 
preparations, FT3, or complex FT4 with FT3 are also 
available on the market, a number of scientific societies, 
including the ETA, ATA, and the American Association 
of Clinical Endocrinologists (AACE), do not recommend 
their use. In the lack of available studies confirming 
higher efficacy of combined therapy with FT3 and FT4, 
it seems that the synthetic sodium of levorotatory thy-
roxine in oral supply, whether in tablet or liquid form, 
should now be the standard treatment for hypothyroid-
ism, regardless of its cause [32–35].
In light of the epidemiological recommendations 
during the COVID-19 pandemic, including social 
distancing, as well as limitations in access to personal 
visits to specialist clinics and additional examinations, it 
is recommended that patients with recently diagnosed 
hypothyroidism, despite the lack of knowledge of the 
exact diagnosis of this disease, should implement an ap-
propriate L-T4 substitution therapy as part of online 
telephone advice or videoconferencing [5, 6], bearing 
in mind that full diagnostics should be supplemented 
as soon as possible as the availability of laboratory and 
imaging tests is restored.
It should be emphasised that L-T4 substitution treat-
ment in full due dose should be implemented in preg-
nant women, newborns, and young adults with a short 
history of disease, while in elderly patients over 50–60 
years of age and those at risk of cardiovascular diseases 
the therapy should be started with a small dose with 
a plan to increase it in the following days and weeks of 
treatment. The most stable absorption of L-T4 in tablet 
form occurs during fasting from 30–60 minutes before 
breakfast or at least 3–4 hours after the last meal. Given 
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of patients, may also increase the risk of severe course 
of COVID-19 infection. Therefore, a proper diagnosis 
should be made as soon as possible, and appropriate 
therapy should be undertaken [37–39].
In the times before the outbreak of the pandemic, 
when access to a specialist and laboratory tests was 
much easier, it was not very difficult to make a proper 
diagnosis of hyperthyroidism. The clinical symptoms 
vary according to age, gender, incidence of coexisting 
diseases, and duration of the disease and its cause. In 
most patients with explicitly defined thyrotoxicosis, 
elevated concentrations of free thyroid hormones 
FT3 and/or FT4 and TSH suppression are observed 
[37, 40, 41].
There is no evidence to date that patients with 
poorly controlled hyperthyroidism are at greater risk of 
systemic viral infection. However, it cannot be excluded 
that these patients have a higher risk of complications, 
including the development of thyroid crisis, caused by 
any infection, including SARS-CoV-2 [6]. Therefore, 
in such a situation, patients with recently diagnosed 
hyperthyroidism should be quickly diagnosed and 
covered with appropriate treatment.
The diagnostic and aetiological process will certainly 
be helpful: medical history (pregnancy, iodine con-
tamination, use of antiarrhythmic medicinal products 
including amiodarone, exposure to iodine-contrasting 
agents and genetic burden), physical examination, hor-
monal tests (TSH, FT4, FT3), immunological determina-
tions: thyrotropin receptor antibodies (TRAbs), thyroid 
peroxidase antibodies (TPOAbs), thyroglobulin anti-
bodies (TgAbs), human chorionic gonadotropin (hCG), 
and imaging. On the basis of an individual analysis of 
each case of hyperthyroidism, the physician should be 
able to decide on the best way to carry out the medi-
cal service in a specialist clinic, taking into account the 
current possibilities of telemedicine (teleconferencing, 
videoconferencing), make a personal visit, and even 
consider referring the patient directly to the hospital for 
hospitalisation. However, it is important to remember 
that it may be difficult or impossible to objectify the 
patient’s ailments with a clinical examination during 
a distance visit. Therefore, any suspicion of thyrotoxi-
cosis based on the clinical symptoms observed by the 
patient should be confirmed by laboratory tests [5, 42, 
43]. However, always, regardless of the availability of 
tests in every patient in whom we have confirmed or 
suspected hyperthyroidism, the severity of symptoms 
should be assessed, as well as the risk of exacerbation 
of coexisting diseases. In all cases of life- and/or health 
threatening conditions, the patient should be urgently 
referred to hospital [5].
Beginning antithyroid therapy (ATD) (methima-
zoles, MMI) and propylthiouracil (PTU), and its de-
the limited access to specialist outpatient clinics, and 
thus less control over the enforcement of therapeutic 
recommendations, even in non-cooperative patients, 
a full weekly substitution dose can be administered once 
a week [19, 36]. In addition, it is important to note that 
the e-prescription formula allows for the prescription 
of a 12-month treatment, although the patient receives 
the drug in 2 doses every 6 months.
In the times before the outbreak of pandemic, it 
was recommended to assess the serum TSH levels 
6–8 weeks after the inclusion of treatment and every 
6–12 months after the equalisation. During pregnancy, 
monthly TSH monitoring with fT4 was recommended 
[17, 19]. However, in the current epidemiological situa-
tion, if regular monitoring of TSH levels is not possible 
and the patient taking the previously recommended 
dose of L-T4 feels well, it is possible to extend the time 
of TSH control. If, on the other hand, there is a feeling 
of malaise or a significant change in body weight, TSH 
determination seems to be necessary. A special group 
of patients included in the current recommendations 
are pregnant women. During pregnancy, the dose of 
L-T4 should be increased, even if monitoring of thyroid 
function becomes difficult, with the recommendation to 
follow the principle “Stay at home to protect yourself 
and your baby” [5, 18].
In the period of difficult access to general practi-
tioners and specialists, as well as laboratory tests, it is 
not recommended to discontinue the existing therapy. 
In the absence of a personal visit, a video conference 
or telephone advice should be preferred. If possible, 
a long-term therapeutic plan should be scheduled, 
informing the patient about the possibilities of safe 
purchase of drugs and the principle of not collecting 
excessive medical devices during a pandemic [17].
Selected aspects of hyperthyroidism 
diagnostics and treatment
Hyperthyroidism is a much greater thyreological chal-
lenge compared to hypothyroidism. It is estimated 
that this endocrinopathy occurs in Europe in about 
0.8% of the population, while in the United States of 
America the rate is 1.3%. The number of cases increases 
with age and more often affects women. It should be 
emphasised that from the moment of diagnosis, it 
requires an in-depth examination by an experienced 
endocrinologist. Both recently diagnosed and already 
treated, but poorly controlled, hyperthyroidism is 
a risk of severe SARS-CoV-2 infection. It is also worth 
highlighting that changes in the cardiovascular system, 
including cardiac arrhythmias, thrombotic events, and 
exacerbation of circulatory or coronary insufficiency, 
which constitute a serious threat to the health and life 
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rivative carbimazole, it is necessary to remember that 
the use of this group of medications requires special 
attention. Approximately 13% of patients, especially in 
the first 3 months of treatment, experience side effects, 
and their frequency depends on the dose of thyrostatic 
medicine used. The most frequent reports are itchy 
generalised or localised rash on the torso, joint pain, 
fever with symptoms suggestive of pharyngitis, and 
less frequently nausea, abdominal pain, or melaena 
with accompanying dark urine [44–46]. However, the 
greatest risk during oral ATD is agranulocytosis, as this 
is a life-threatening condition and is an urgent indica-
tion for hospitalisation, although it is observed in less 
than 0.5% of patients. Neutropaenia is usually charac-
terised by fever and sore throat, sometimes accompa-
nied by oral ulceration, which in the era of COVID-19 
pandemic may suggest a mild form of SARS-CoV-2 
infection (fever, dry cough, fatigue, flu-like symptoms). 
These symptoms may be difficult to distinguish, both 
for the patients and their physicians; thus, in the case 
of a justified suspicion of neutropaenia, the patient 
should be advised to immediately discontinue ATD and 
perform an urgent peripheral blood morphology. It is 
worth noting that in COVID-19 infection lymphopaenia 
and thrombocytopaenia are observed, but they are not 
contraindications for anti-thyroid therapy [5, 6, 17]. The 
absolute contraindications are agranulocytosis, toxic 
liver damage, and vasculitis [44]. Therefore, prior to the 
inclusion of ATD the blood count should be examined 
with a smear and the transaminase activity should be 
determined. If, due to epidemiological reasons and 
limited access to primary healthcare resources, it is 
not possible to perform these tests, it is recommended 
that ATD treatment be discontinued and the patient 
be observed. If symptoms disappear within a week, 
treatment may be continued, and if they become 
more severe during discontinuation or relapse after 
re-admission, the patient should be advised to contact 
his/her endocrinologist or primary care physician im-
mediately [5,1 7].
In the era of the SARS-CoV-2 pandemic, the 
“Block-Replace Regimen (BRR)” combination therapy 
scheme may be considered, given the reduced avail-
ability of laboratory tests. It allows for less frequent 
control of thyroid function and prevents enlargement 
and the occurrence of hypothyroidism phase. However, 
it is important to remember that it brings a higher risk 
of side effects. The exact scheme of combination treat-
ment of BRR is shown in Figure 1 [5, 43]. 
In selected cases where, despite the use of oral ATD 
therapy or due to its side effects, it has not possible to 
obtain the disease control, it is recommended to try to 
Figure 1. Combination therapy “Block-Replace Regimen (BRR)” in the treatment of hyperthyroidism in adult patients during 
the COVID-19 pandemic, according to Boelaert et al. [5]
Thyreotoxicosis     Ø TSH    ≠ FT3    ≠ FT4 
FT4 — 30 pmol/L FT4 — 30–60 pmol/L FT4 > 60 pmol/L 
Thiamazole 15 mg/day Thiamazole 30 mg/day 
FT4 — 30 pmol/L FT4 — 30 pmol/L FT4 — 30 pmol/L 
Continuation thiamazole 30 mg/day
Add L-T4: 75 µg if body weight < 55 kg, 100 µg if body weight > 55 kg
After 6 months, endocrinological reassessment, ideally in a hospital setting
176





refer the patient to urgent surgery or to use radioactive 
iodine therapy [46].
Graves’ disease is one of the main symptoms of 
hyperthyroidism, and one of its non-thyroidal com-
plications is a syndrome of ophthalmic symptoms 
caused by immunological inflammation of muscles, 
as well as adipose tissue and connective tissue of 
orbits — so-called thyroid-associated orbitopathy. 
In anti-inflammatory therapy, weekly intravenous 
glucocorticosteroids (GKS) are usually used [47]. 
Unfortunately, due to the immunosuppressive effect 
of GKS, the patients treated by us are more exposed 
to SARS-CoV-2 infection, and this also applies to the 
therapy with modern drugs such as mycophenolate, 
azathioprine, or antibody-class drugs: rituximab, 
teprotumumab, and tocilizumab [48]. Therefore, to-
gether with the patient, we should try to minimise 
the risk of infection by adapting to the safety rules 
recommended by the Ministry of Health, as well as the 
European Endocrine Society, which advises 12-week 
isolation for these patients [49]. On the other hand, it 
is important to remember that immunosuppressive 
treatment should absolutely not be discontinued. The 
treating physician, considering the benefits and risks 
in a specific epidemiological situation, should be able 
to finally decide on the continuation of treatment. 
One option, if it is not possible to administer GKS IV, 
is to replace the therapy with an oral form, for the 
patient to receive treatment at home. Additionally, 
in preventing the progression of orbitopathy, it is 
recommended that smoking be avoided, both actively 
and passively, and/or to enhance the effects with sele-
nium preparations [50]. In the paper Xia J et al. it was 
indicated that conjunctivitis may be one of the symp-
toms of COVID-19 infection, because the presence of 
SARS-CoV-2 mRNA was detected in tears. Therefore, 
patients with orbitopathy in whom COVID-19 has 
been confirmed represent a significant risk of infec-
tion, especially when soft tissues of the orbit are also 
occupied. It is necessary to make these patients aware 
of the recommended precautions to prevent infection 
with the SARS-CoV-2 virus. The WHO recommends 
keeping a safe distance from other people, i.e. social 
distancing, covering the nose and mouth, as well 
as washing and disinfecting hands thoroughly and 
regularly [51].
An equally important group of patients with hy-
perthyroidism are pregnant women. This particular 
group of patients should be particularly careful and 
should, as much as possible, implement all personal 
protective equipment to protect against SARS-CoV-2 
infection [52]. During the COVID-19 pandemic, it is 
recommended that the therapy of hyperthyroidism 
in pregnant women should be carried out according 
to the current standards of management. In the first 
trimester of pregnancy (up to 16 weeks), the PTU and 
then MMI should be treated with the lowest possible 
dose of ATD [53]. When starting MMI therapy, it is 
important to remember to inform the patient about 
possible teratogenic effects of the drug on the foetus 
[54]. It is important to point out that BRR therapy is 
contraindicated in pregnant women.
Conclusions
Many international scientific societies, including the 
International Thyroid Federation, emphasise that 
there is currently no evidence that patients with 
thyroid diseases are more likely to be infected with 
SARS-CoV-2. There is also no evidence that people 
with poorly controlled thyroid disease are more likely 
to be infected. However, it is important to remember 
that the pandemic and resulting epidemiological 
regime may cause difficult access to basic and special-
ist health care. In order to prevent the spread of the 
SARS-CoV-2 virus, it is recommended that the need 
for personal visits to a specialist physician be mini-
mised, with contacting a telemedicine provider being 
preferred. Direct visits should be dedicated only to 
selected groups of patients requiring personal contact 
with the physician.
Due to the possibility of difficult access to specialised 
laboratory and imaging tests, it is recommended that 
patients with recently diagnosed hypothyroidism or 
hyperthyroidism start treatment as soon as possible, 
with the possibility of postponing additional tests to 
establish the full aetiology of the disease. In the case of 
patients already treated, it is important to emphasise 
the necessity of continuing the existing treatment. It is 
recommended that the physician providing treatment 
be contacted on a regular basis via telecommunication. 
Physicians, including endocrinology specialists, should 
educate their patients in the use of virtual advice and 
various social platforms, and thus limit personal visits 
during the pandemic.
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